Luye Pharma Group Ltd.

Luye Pharma Group Ltd. logo
🇨🇳China
Ownership
Public
Established
2014-04-28
Employees
5.2K
Market Cap
-
Website
http://www.luye.cn

Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder

First Posted Date
2022-04-11
Last Posted Date
2024-03-19
Lead Sponsor
Luye Pharma Group Ltd.
Target Recruit Count
89
Registration Number
NCT05321602
Locations
🇺🇸

Woodland International Research Group, Little Rock, Arkansas, United States

🇺🇸

CNS Research, Garden Grove, California, United States

🇺🇸

NRC Research Institute, Orange, California, United States

and more 6 locations

A Dose-escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetic of LPM3770164 in Healthy Subjects

First Posted Date
2022-02-14
Last Posted Date
2024-01-29
Lead Sponsor
Luye Pharma Group Ltd.
Target Recruit Count
104
Registration Number
NCT05238701
Locations
🇨🇳

Shanghai Mental Health Center, Shanghai, Shanghai, China

Pharmacokinetics, Pharmacodynamics and Safety of LY01005 in Patients With Prostate Cancer Compared to ZOLADEX®

Phase 1
Completed
Conditions
Interventions
First Posted Date
2021-12-01
Last Posted Date
2023-05-16
Lead Sponsor
Luye Pharma Group Ltd.
Target Recruit Count
23
Registration Number
NCT05140512
Locations
🇨🇳

Sun Yat-sen Memorial Hospital of Sun Yat-sen University, Guangzhou, China

Efficacy and Safety of LY01005 in Patients With Breast Cancer Compared to ZOLADEX®

Phase 3
Completed
Conditions
Interventions
First Posted Date
2021-11-05
Last Posted Date
2023-05-16
Lead Sponsor
Luye Pharma Group Ltd.
Target Recruit Count
188
Registration Number
NCT05110170
Locations
🇨🇳

Zhejiang Cancer Hospital, Hangzhou, China

A Study to Evaluate the Efficacy and Safety of LY06006 in Postmenopausal Women With Osteoporosis at High Risk for Fracture

Phase 3
Conditions
Interventions
First Posted Date
2021-09-29
Last Posted Date
2021-09-29
Lead Sponsor
Luye Pharma Group Ltd.
Target Recruit Count
448
Registration Number
NCT05060406
Locations
🇨🇳

Shanghai Sixth People's Hospital, Shanghai, Shanghai, China

A Study to Evaluate LY06006 and Prolia in Healthy Adults

Phase 1
Conditions
Interventions
First Posted Date
2021-07-22
Last Posted Date
2021-07-22
Lead Sponsor
Luye Pharma Group Ltd.
Target Recruit Count
168
Registration Number
NCT04973722
Locations
🇨🇳

The Third Xiangya Hospital of Central South University, Changsha, Hunan, China

A Phase I Study of LY-CovMab Injection in Chinese Healthy Subjects

Phase 1
Conditions
Interventions
First Posted Date
2021-07-22
Last Posted Date
2021-07-22
Lead Sponsor
Luye Pharma Group Ltd.
Target Recruit Count
42
Registration Number
NCT04973735
Locations
🇨🇳

The Second Hospital of Anhui Medical University, Hefei, Anhui, China

Relative Bioavailability of LY03010 Compared to Listed Drug

First Posted Date
2021-06-10
Last Posted Date
2023-04-25
Lead Sponsor
Luye Pharma Group Ltd.
Target Recruit Count
281
Registration Number
NCT04922593
Locations
🇺🇸

Uptown Research Institute, LLC, Chicago, Illinois, United States

🇺🇸

Innovative Clinical Research, Inc., Miami Lakes, Florida, United States

🇺🇸

Collaborative Neuroscience Network, Inc., Garden Grove, California, United States

and more 5 locations

Efficacy and Safety of LY01011 and Xgeva® in Patients With Bone Metastases From Solid Tumors

First Posted Date
2021-04-26
Last Posted Date
2021-06-07
Lead Sponsor
Luye Pharma Group Ltd.
Target Recruit Count
850
Registration Number
NCT04859569
Locations
🇨🇳

The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, China

A Study to Evaluate the Efficacy and Safety of Ansofaxine Hydrochloride Extended-release Tablets in the Treatment of Major Depressive Disorder (MDD)

First Posted Date
2021-04-21
Last Posted Date
2021-11-15
Lead Sponsor
Luye Pharma Group Ltd.
Target Recruit Count
558
Registration Number
NCT04853407
Locations
🇨🇳

The Sixth Hospital of Peking University, Beijing, China

© Copyright 2024. All Rights Reserved by MedPath